The latest report from ResearchAndMarkets.com, titled Spondyloarthritis (Spondyloarthropathy) – Global Clinical Trials Review, 2025, provides a panoramic breakdown of clinical trial activity in spondyloarthritis across G7 and E7 countries. Based on data from over 80 sources including trial registries and journals, the report categorizes trials by region, phase, status, endpoints, and sponsor type, while identifying leading drugs and sponsors with the highest ongoing activity.
What emerges from this data is not just a quantitative snapshot but a deeper view into the development fragmentation in inflammatory joint diseases, particularly spondyloarthritis subtypes such as ankylosing spondylitis and psoriatic arthritis. Despite high global disease burden and commercial presence from major pharmaceutical companies, the clinical development landscape remains lopsided in regional intensity, trial phase advancement, and sponsor concentration.
What this reveals about geographic gaps and asymmetries in trial volume
One of the most striking observations from the 2025 dataset is the geographic asymmetry in trial activity. While G7 countries predictably dominate total trial count and completed trials, the rise of E7 countries in early-phase or observational studies signals shifting trial site dynamics—but not necessarily clinical development leadership.
Countries such as India and China are increasingly hosting trials, often due to faster enrollment, lower costs, and growing musculoskeletal disease burden. However, industry observers note that most of these trials remain in earlier stages (Phase I or II), with limited participation in pivotal studies. The gap between early- and late-phase development in these regions suggests that while E7 markets are becoming essential for trial execution, they remain under-leveraged in global regulatory or post-approval strategies.
In contrast, Western Europe and the United States continue to lead in Phase III and IV trials, especially for biosimilars and biologic-origin therapies, reinforcing the regulatory primacy of EMA and FDA jurisdictions in shaping development timelines and endpoints.
What the sponsor distribution tells us about consolidation risks
The report also underscores the outsize role of a few multinational pharmaceutical companies in advancing therapies for spondyloarthritis. Among the top sponsors featured are Novartis AG, AbbVie Inc., Johnson & Johnson, Pfizer Inc., Eli Lilly and Company, and Merck & Co. Inc., all of which maintain portfolios in interleukin or TNF-alpha inhibitor classes.
This concentration raises both strength and fragility signals. On the one hand, a focused sponsor base brings capital, trial site infrastructure, and continuity in biologic innovation. On the other hand, it exposes the field to risk if any one sponsor reprioritizes, exits, or sees setbacks in its lead molecule. For example, shifts in patent protection or biosimilar pressures on TNF-inhibitor mainstays could discourage long-term investment in the category unless new mechanisms show commercial viability.
Some new sponsors—such as Zhuhai Rundu Pharmaceutical Co. Ltd. and Asia Pharmaceutical Group (Hainan) Co. Ltd.—signal increasing Asian interest in developing differentiated biologics or small molecules. However, these efforts are typically limited in cross-border regulatory ambition, rarely submitting for simultaneous approval in ICH regions.
Why trial endpoints and dropout trends matter more than ever
A valuable dimension of the report lies in its assessment of endpoint completion and trial withdrawal reasons. While global enrollment trends show a gradual increase, particularly in E7 countries, trial suspension and withdrawal rates remain high—especially in Phase II studies where endpoints are not clearly defined or fail to meet efficacy bars.
Industry analysts caution that in spondyloarthritis, composite endpoints such as ASAS20, BASDAI, or ACR response scores introduce trial design complexity. Coupled with heterogeneity across subtypes—axial, peripheral, enthesitis-related—this increases statistical variability and trial risk. Moreover, the impact of patient-reported outcomes, fatigue, and imaging endpoints often makes early readouts difficult to interpret.
A key takeaway is that clinical success hinges less on enrollment scale and more on protocol clarity, real-world relevance of endpoints, and inclusion of biomarkers. Without standardization of outcome measures across subtypes, regulatory approval remains a moving target.
What’s missing: biosimilars, head-to-head trials, and early signal readouts
Despite increasing trial volume, the report reveals a lack of biosimilar-driven comparative trials—a missed opportunity given the maturity of several blockbuster biologics in the space. Few trials appear to investigate interchangeability, switching protocols, or cost-effectiveness of biosimilars compared to originators in ankylosing spondylitis or psoriatic arthritis.
Similarly, direct head-to-head trials between TNF-alpha and IL-17 or IL-23 inhibitors remain rare. Clinicians tracking treatment sequencing in real-world settings point out that post-failure positioning of newer mechanisms remains unclear due to this evidence gap. This limits treatment personalization and payer confidence in coverage models.
Moreover, there is limited data on predictive biomarkers or pharmacogenomic profiling in ongoing trials. As precision immunology advances in oncology and inflammatory bowel disease, spondyloarthritis development still appears to lag in embracing early stratification models that could improve responder targeting and reduce trial attrition.
How regulators might interpret the evolving data landscape
For regulators, the expanding but uneven trial landscape presents both opportunities and challenges. On the positive side, the breadth of ongoing studies improves global safety datasets, especially in underrepresented populations. Regulatory watchers suggest this could facilitate bridging strategies and multi-region submissions if sponsors align on trial endpoints and quality standards.
However, the sheer heterogeneity of trial designs and endpoint reporting makes meta-analysis or comparative effectiveness modeling difficult. Without harmonization in statistical methods, trial duration, and imaging standards (e.g., MRI-based scoring), regulators may face difficulty interpreting the cumulative evidence for newer agents.
Moreover, the lack of pediatric trials and limited exploration of long-term disability or work productivity endpoints may hamper broader policy relevance and health technology assessments, particularly in nationalized systems.
What industry stakeholders should watch next
As the global clinical pipeline for spondyloarthritis expands, several fault lines remain. Trial execution is no longer the bottleneck, but protocol relevance, trial design harmonization, and real-world translatability are growing concerns.
Industry observers will be closely watching whether next-generation therapies—such as TYK2 inhibitors or novel small molecules—can demonstrate durable remission with better safety and convenience than current injectables. Equally, regulatory interest in comparative trials, biomarker integration, and digital endpoint validation may soon become a gating factor for Phase III progression.
With biosimilar economics putting pressure on pricing and reimbursement, sponsors may also be forced to invest in post-approval trials to defend market access. Payers and providers alike will demand clearer differentiation in mechanism, efficacy onset, durability, and safety.
Ultimately, the field may need to move from drug-first to disease-first trial design, embracing adaptive protocols and outcome measures that reflect patient journey complexities across the spectrum of axial and peripheral spondyloarthropathies.
Can a global trials map help fix spondyloarthritis’s fragmented development landscape? added by Pallavi Madhiraju on
View all posts by Pallavi Madhiraju →